Publications:
Our Research

Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters

A randomized first-in-human Phase 1 trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults

Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study

Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States

Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARSCoV-2

Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines

The Novavax Heterologous COVID Booster Demonstrates Lower Reactogenicity Than mRNA: A Targeted Review

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-cov-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

Biodistribution of the Saponin-Based Adjuvant Matrix-M™ Following Intramuscular Injection in Mice

XBB.1.5 spike protein COVID‑19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants